Abstract: The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to polypeptides found in extracellular microvesicles as diagnostic and screening markers, and clinical targets for cancer (e.g., prostate cancer).

Abstract: The present invention relates to disulphide bond stabilized recombinant MHC class II molecules. In particular, the present invention provides a recombinant MHC class II molecule, which comprises: (i) all or part of the extracellular portion of an MHC class II ? chain; (ii) all or part of the extracellular portion of an MHC class II ? chain; wherein (i) and (ii) provide a functional peptide binding domain and wherein (i) and (ii) are linked by a disulphide bond between cysteine residues located in the ?2 domain of said ? chain and the ?2 domain of said ? chain, wherein said cysteine residues are not present in native MHC class II ?2 and ?2 domains. Methods of producing these molecules in prokaryotic systems and various uses of these molecules form further aspects.

Abstract: The present invention relates to compositions and methods for treating cancer. In particular, the present invention relates to EpCAM-targeted immunotoxins and uses thereof in treating peritoneal cancers expressing EpCAM (e.g., colorectal, ovarian, and pancreatic cancer).

Abstract: A zone location system with ultrasound US transmitters S1, S2, S3 located in respective zones Z1, Z2, Z3 such as rooms of a building B. Preferably, the US transmitters are time-multiplexed so that each of them in turn transmits a US signal US with a unique ID code USID represented therein. The portable tag PT includes an ultrasound receiver USR arranged to receive the US signal. Based on the received US signal, the portable tag PT measures a strength of the received US signal. The portable tag PT also measures a parameter related to a movement of the portable tag PT, e.g. a Doppler shift based on the received US signal. Further, the portable tag extracts the USID. Then it transmits a wireless Radio Frequency signal RFS with its own ID PTID, the USID and first and second data values D1, D2 representing the signal strength and the movement related parameters.

Abstract: The present invention relates to polypeptides that bind to H3K4 methylated chromatin, and in particular to the use of reagents comprising such polypeptides for epigenetic/epigenomic analysis.

Abstract: The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Abstract: The invention provides a method, an image analysis software product, and a system for medical imaging analysis for estimating contrast agent extravasation in contrast agent based perfusion imaging such as MRI dynamic contrast enhanced (DCE) imaging, and in particular correction, compensation, or visualization of extravascular leakage of contrast agent in tumors. According to the invention, the effect of extravasation is directly manifested in the tail part of an observed, apparent residue function, R?(t), obtained directly by de-convoluting the expression C(t)=R?(t)Cp?(t) with the arterial input function (AIF). A leakage rate or extravasation constant is determined directly from the tail part of the determined apparent residue function.

Abstract: A method of estimating the true uptake of a tracer in a physiological image acquired with a physiological image modality that has limited spatial resolution comprises: co-registering an anatomical image volume and the physiological image volume such that both image volumes have corresponding voxels; segmenting the anatomical image volume into a number of non-overlapping anatomical regions; combining each of the segmented anatomical regions with a function representative of the limited spatial resolution of the physiological image modality to generate a blurred anatomical region volume for each of the segmented regions; assuming the physiological image in each voxel to be a linear sum of the image intensities of the corresponding voxels in the blurred region volumes in that voxel; estimating, for each voxel, a value representative of the contribution to that voxel from each blurred region volume based on the uptake measured by the physiological image for that voxel and for nearby voxels; and using the estimate

Abstract: A peptide comprising a unit of formula (I) and having a molecular weight of less than 2000 wherein each X is independently an organic group, e.g. a C1-6 alkyl or C1-6 alkenyl group, preferably —CH2—CH?CH2, or the two X groups taken together can form a covalent or non-covalent link between the two O groups, preferably a C1-10 saturated or unsaturated carbon chain optionally interrupted by one or more heteroatoms selected from O, S, N, P, or Si, especially a C3-10 carbon chain or one X represents an azido group and the other an C2-6-alkynyl group; both Z's are the same and are O or S; each Y is independently C, CH, CH2, N or NH; R1 is H or C1-6 alkyl; R2 is H or C1-6 alkyl; R5 is a C1-6 alkyl group, preferably isopropyl; or a salt, ester or prodrug thereof.

Abstract: The current disclosure generally relates to the field of saxitoxins and the identification of microorganisms capable of producing them. In particular, the saxitoxin A (sxtA) gene comprising catalytic domain sequences saxitoxin A1 (sxtA1) and saxitoxin A4 (sxtA4) is identified in a number of dinoflagellate species. The disclosure relates to methods of detection of saxitoxin-producing dinoflagellates by amplification and detection of the sxtA gene (in particular by PCR) and kits and primers for use in the method are also disclosed. Saxitoxin-producing dinoflagellate genera detected by the method include Alexandrium, Pyrodinium or Gymnodinium.

Abstract: The invention provides novel Zr MOFs, in particular compounds having a surface area of at least 1020 m2/g or if functionalized, having a surface area of at least 500 m2/g.

Abstract: The present invention relates to methods and biomarkers (e.g., epigenetic biomarkers) for detection of gastrointestinal cancers (e.g., colorectal cancer, gastric cancer, pancreatic cancer, liver cancer, cancer of the gall bladder and/or bile ducts (e.g., cholangiocarcinoma)) in biological samples (e.g., tissue samples, stool samples, blood samples, plasma samples, cell samples, gall samples, bile samples, serum samples).

Abstract: The present invention relates to compounds of formula (I), to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy: Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway and increased presence of nuclear ?-catenin. For example, these may be used in preventing and/or retarding proliferation of tumor cells and metastasis, for example carcinomas such as colon carcinomas.

Abstract: The present invention relates to methods for predicting the risk for ventricular arrhythmias in a subject who has previously suffered a myocardial infarction (MI) or suffers from a primary cardiomyopathy, said method comprising measuring the myocardial mechanical dispersion in said subject and estimating the risk for ventricular arrhythmias based on said measurements. Similar the invention relates to a method for evaluating whether a subject is a candidate for implantable cardioverter-defibrillator (ICD) therapy.

Abstract: The present invention relates to the use of a dinQ-sRNA type I toxin-antitoxin systems for plasmid maintenance. An embodiment of the present invention relates to the use of the dinQ-sRNA type I toxin-antitoxin system for the manufacture of a plasmid selection system. In another embodiment of the present invention is the sRNA selected from the group consisting of agrA and agrB. Aspects of the present invention also relates to medical uses of the plasmid selection system.

Abstract: The present invention relates to a method for determining or predicting the response of a patient diagnosed with locally advanced rectal cancer to chemoradiotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with rectal cancer to specific medicaments, radiotherapy and/or chemotherapy. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles in samples of said patients.

Abstract: The present invention relates to methods and kits for the detection of 5-hydroxymethylcytosme (5hmC). In some embodiments, the present invention relates to methods and kits for detection of 5hmC in nucleic acid (e.g., DNA, RNA). In some embodiments, the present invention relates to detection of 5hmC in genomic DNA, e.g., mammalian genomic DNA.

Abstract: The invention relates to sweat activity measurement, e.g. for determining a physiological state of a subject, embodied by a method as well as a kit with an immittance measuring circuit and electrodes with contact electrolyte. Sweat activity is considered a transport phenomenon and can be defined as a flux, e.g. gram water per skin area per second. Prior art methods determining water absorbed per gram dry stratum corneum measures skin moisture and do not truly reflect sweat activity. A periodic signal with frequency of 60 Hz or lower is applied to reduce contribution from complex admittance of the skin, and skin conductance is measured as a degree of sweat activity. The contact electrolyte allows filling of sweat ducts with sweat from sweat glands, this may be characterized in that it does not substantially fill the sweat ducts when being positioned on the skin and/or in that it has a re-absorption time constant from the sweat ducts into the Epidermis of less than 15 min.

Abstract: The invention relates to methods and biomarkers (e.g., epigenetic biomarkers) for detection of bladder cancer in biological samples (e.g., tissue samples, urine samples, urine sediments). In some embodiments, methods and biomarkers of the present invention find use in discriminating between bladder cancer, prostate cancer and renal epithelial tumors.

Abstract: The invention relates to medical monitoring apparatuses, methods, and computer programs for determining power or work as a function of time for individual myocardial segments based on strain and pressure measurements. Compared to prior art determinations of determination of mechanical power or work for individual segments, the invention is advantageous as it provides such determination solely from a pressure measurement or estimate and a measurement of strain, preferably by echocardiography, such as speckle tracking ultrasound imaging. This allows a fast, easy and non-invasive determination with high temporal and spatial resolution. A number of indices for segment work can be calculated which can be used as markers for the individual segment function as well as for a selection of patient for CRT.